Skip to content Skip to left sidebar Skip to right sidebar Skip to footer

Tag: #LifeSciences

Amgen to Establish New Science and Innovation Centre in Hyderabad’s Genome Valley

Global biopharmaceutical giant Amgen is doubling down on its commitment to India, announcing plans to open a state-of-the-art Science and Innovation Centre in Hyderabad’s premier Genome Valley. Slated to become operational in 2027, this new facility will mark a significant expansion of Amgen’s global research and development (R&D) network, which currently comprises seven research laboratories worldwide.

Bridging Wet-Lab Science and Digital Innovation

The new Hyderabad centre is designed to be a powerhouse of discovery. It will focus on critical, high-impact areas including:

  • Discovery Chemistry
  • Drug Metabolism and Pharmacokinetics (DMPK)
  • Precision Medicine
  • Data Science and Digital Technologies

By integrating experimental “wet-lab” science with advanced data analytics and AI-driven tools, the centre aims to dramatically accelerate the discovery and development of life-saving medicines. This facility will seamlessly complement Amgen’s existing Global Capability Centre (GCC) in Hyderabad, creating a powerful synergy between digital innovation and hands-on biological research.

Why Hyderabad? A Thriving Life Sciences Ecosystem

Hyderabad has long been recognized as India’s “Genome Valley,” but this new investment signals a shift from manufacturing and clinical research to high-value, early-stage discovery.

D. Sridhar Babu, Telangana’s Minister for IT and Industries, praised the decision, highlighting the state’s robust ecosystem: “Hyderabad brings together scientific talent, technology, and industry at scale and has built one of the world’s strongest life sciences ecosystems, with deep capabilities in pharmaceuticals and vaccines. The next chapter is about taking that strength into discovery and innovation. Our ambition is to make Hyderabad a place where the next generation of medicines and therapies can be discovered, developed, and taken to the world.”

Leadership Perspectives on Global Integration

For Amgen, this move is about creating a truly interconnected global R&D footprint.

Jay Bradner, Executive Vice President of Research and Development, Artificial Intelligence, and Data at Amgen, noted that the Genome Valley centre will perfectly complement the company’s strong US-based R&D operations. It will expand Amgen’s ability to connect science, data, and technology across its global research system, translating complex insights into tangible new medicines.

Som Chattopadhyay, Senior Vice President of Global Business Solutions and National Executive at Amgen, emphasized that this development firmly establishes India as a critical, strategic pillar in Amgen’s global R&D network.

Echoing this sentiment, Naveen Gullapalli, Managing Director of Amgen India, highlighted the region’s human capital: “Hyderabad’s STEM talent and life sciences ecosystem will support advanced technologies at scale. Our new centre at Genome Valley will help integrate biotechnology and digital innovation to serve more patients globally.”

Looking Ahead

Amgen’s investment in Hyderabad is a resounding vote of confidence in India’s scientific prowess and its potential to drive global healthcare innovation. As the centre gears up for its 2027 launch, it promises to create high-value jobs, foster cutting-edge research, and cement Hyderabad’s status as a premier global destination for biotech discovery and digital health innovation.

The future of medicine is being written in Hyderabad, and Amgen is ready to lead the next chapter.

Sanofi Expands Hyderabad GCC, Adds Nearly 2,000 Jobs in India

French pharmaceutical giant Sanofi is deepening its commitment to India with a major expansion of its Global Capability Centre (GCC) in Hyderabad. The company plans to add nearly 2,000 new jobs, increasing total headcount at the centre from over 2,600 employees to more than 4,500 professionals.

The expansion reflects Sanofi’s long-term strategy to strengthen its global operations by leveraging India’s growing pool of high-skilled talent in research, technology, and digital innovation.

Significant Investment to Support Growth

The expansion will be backed by a multi-hundred-million-dollar investment, though the company has not specified an exact hiring timeline. This move builds on Sanofi’s 2024 commitment to invest €400 million (approximately $474.6 million) in its India GCC operations by the end of the decade.

The investment signals a shift toward scaling high-value functions in India, positioning the Hyderabad centre as a critical part of Sanofi’s global ecosystem.

Focus on Innovation and Advanced Capabilities

The additional roles will span across several strategic domains, including:

  • Research & Development (R&D)
  • Artificial Intelligence (AI)
  • Data Innovation and Analytics
  • Medical Affairs
  • Commercial Capabilities
  • Corporate Functions

This indicates that Sanofi’s Hyderabad centre is evolving beyond traditional support services into a global innovation hub that contributes directly to enterprise-wide strategy and transformation.

India’s Growing GCC Ecosystem

Sanofi’s expansion comes at a time when India’s Global Capability Centre ecosystem is witnessing rapid growth. According to Anarock:

  • India hosts more than 1,700 GCCs
  • These centres employ over 1.9 million professionals
  • The GCC market could grow to $105–110 billion by 2030
  • The number of centres may exceed 2,400 by the end of the decade

What were once considered cost-efficient back-office operations have now transformed into innovation-led centres driving digital transformation, R&D, finance, and global operations.

Hyderabad: A Strategic Pharma Hub

Hyderabad has increasingly become a focal point for global life sciences and technology companies. The announcement precedes the city’s flagship biotechnology conference, BioAsia, where global pharmaceutical leaders such as Eli Lilly, Novo Nordisk, Merck, and Sanofi are expected to discuss research expansion and India’s pharmaceutical growth trajectory.

The timing further underscores Hyderabad’s growing importance in global healthcare innovation.

A Strategic Shift in Global Operations

For Sanofi, the Hyderabad GCC is emerging as a cornerstone of its global strategy. As pharmaceutical companies rebalance supply chains and invest heavily in digital capabilities, India’s skilled workforce and strong ecosystem make it a preferred destination for long-term investment.

This expansion not only strengthens Sanofi’s operational capabilities but also reinforces India’s position as a global hub for advanced research, AI, and pharmaceutical innovation.

Telangana to Deepen Strategic Ties with North-East for Tech and Development Push

Telangana has announced plans to play a more active role in the growth and development of India’s North-Eastern States, with IT and Industries Minister D. Sridhar Babu unveiling the Telangana–North East Connect (Phase-2) initiative at Raj Bhavan in Hyderabad on Tuesday.

The State government is preparing a comprehensive roadmap to strengthen collaboration with the North-East in key sectors, including digital connectivity, technology adoption, entrepreneurship, skill development, life sciences, bio-innovation, and rural transformation. According to the Minister’s office, the plan aims to accelerate mutual growth by leveraging Telangana’s capabilities and the North-East’s emerging potential.

Highlighting the inclusive ethos of Telangana, Mr. Sridhar Babu noted that the North-Eastern States have made remarkable progress in digital literacy, IT skilling, fintech, and public digital services, despite facing infrastructural and connectivity constraints.

As part of Phase-2 of the initiative, Telangana and the North-East will work together on projects such as a North East–Telangana Tech Corridor, joint innovation labs, bio-incubators, creative technology studios, and green-energy collaborations. The Minister emphasised that Telangana’s development strategy is centred on preparing for future technologies, ensuring the State remains ahead of emerging global trends.